MAM
Indian thriller web-series collects Rs 9 lakh via crowd-funding
NEW DELHI: Indian crowd-funding thriller web series Hankaar, has successfully received Rs 9 lakh, which is more than a lakh of its initial target, with the help of 157 backers.
Hankaar had set a target of Rs 8 lakh in 50 days. The series is slated for release in January next year.
Set in Mumbai in the backdrop of drugs, real-estate dirty deals and prostitution, Hankaar is ‘realistic fiction’ content in the thriller and drama genre. It explores the stories of five ordinary people who go through extraordinary life changing experiences.
The cast includes Sanjay Bhatia, Rajesh Balwani, Ankur Vikal, Ram Menon, Sharda Nand Singh, Priyadarshi P and Yogini Chowk.
The makers say they chose the Internet and not TV channels as these do not look beyond saas-bahu sagas. The content and theme of the series is realistic but not accepted as content to be viewed on mainstream television.
Hankaar went live on Wishberry.in a month ago and surpassed their funding goal with the help of 157 backers who will now be named as co-producers and will also have the chance to give their inputs in the making of the series.
Hankaar director and producer Ravi Iyer said, “We are overwhelmed by the support we got and hope to entertain the audience. We plan to make not one but three seasons of Hankaar.”
With the average Indian spending more than eight hours on the internet and the majority of TV content being aimed at women over 35 years, Iyer felt the time was right to launch the first ever tech thriller web series.
Writer Yogi Chopra said, “As producers we realise that Indian television is not ready for this kind of content. But we are keen to create not just one, but at least three seasons of this series. It is certain that the audience for this type of content is there, but because it is deemed non-commercial, it is difficult to find required funding.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
